PolyPid: 300% Upside Potential – Analyst Buy Rating
- This valuation reflects a potential surge of almost 300% from its current share price, which hovers around $2.80.
- The optimistic forecast hinges on the imminent topline data release from the company's Phase 3 SHIELD II trial, slated for the second quarter of 2025.This trial assesses the...
- Wainwright, suggests the market undervalues D-PLEX100, PolyPid’s primary product.
H.C. Wainwright sees massive potential in PolyPid (PYPD), issuing a “Buy” rating with a $11 target—almost 300% upside. This bullish outlook centers on the anticipated Q2 2025 topline data from the Phase 3 SHIELD II trial, focusing on D-PLEX100’s surgical site infection prevention capabilities. Analyst Brandon Folkes believes the market undervalues this primary product.D-PLEX100, utilizing PolyPid’s PLEX technology, delivers doxycycline for up to 30 days, addressing a significant market. Recent positive signals, including early data reviews and previous subgroup successes, fuel optimism.With a $6.8 billion market chance in abdominal surgeries alone, PolyPid plans partnerships for commercialization. News Directory 3 is watching as the company targets over $300 million in D-PLEX100 revenue. Discover what’s next for this innovative healthcare stock.
PolyPid Stock Gets “Buy” Rating Amid D-PLEX100 Anticipation
Updated June 02, 2025
PolyPid Ltd. (NASDAQ: PYPD) has received a Buy rating from H.C. Wainwright, accompanied by an $11 price target. This valuation reflects a potential surge of almost 300% from its current share price, which hovers around $2.80.
The optimistic forecast hinges on the imminent topline data release from the company’s Phase 3 SHIELD II trial, slated for the second quarter of 2025.This trial assesses the effectiveness of D-PLEX100 in surgical infection prevention.
Brandon Folkes, analyst at H.C. Wainwright, suggests the market undervalues D-PLEX100, PolyPid’s primary product. Folkes sees the upcoming data as a catalyst, presenting a compelling risk/reward scenario for investors.
D-PLEX100 employs PolyPid’s PLEX technology, designed for prolonged, localized delivery of doxycycline directly to surgical sites for up to 30 days. This addresses the meaningful problem of surgical site infections, which impact millions and inflate healthcare costs.
An independent Data Safety Monitoring Board reviewed early data from the SHIELD II trial in December 2024, recommending the study conclude at 800 patients rather of a possible 1,100. Folkes views this as a promising sign regarding the trial’s efficacy.
Prior data has bolstered confidence in D-PLEX100. While a previous trial was affected by COVID-related infection rate declines, strong results within specific patient subgroups supported expectations for positive SHIELD II outcomes.
The company is targeting 4.5 million abdominal surgeries,representing a $6.8 billion market based on projected pricing. PolyPid intends to partner for commercialization to boost adoption of its surgical infection prevention technology.
PolyPid’s PLEX platform has potential beyond D-PLEX100, applicable to various clinical applications. This versatility could unlock future value as the company develops additional programs.
The analyst estimates D-PLEX100 could generate over $300 million in revenue if prosperous. Folkes applies an 80% probability of success in their valuation.
What’s next
The Phase 3 data readout in Q2 2025 could be a turning point for PolyPid, validating its technology and potentially transforming its position in surgical infection prevention.